Cargando…
Immunotherapy in indolent Non-Hodgkin's Lymphoma
Treatment of non-Hodgkin lymphoma (NHL) in general has improved over the years with the emergence of the monoclonal antibodies (MAB) therapy. NHL is divided into B cell NHL and T cell NHL. Treatment of NHL was based on the subtype of NHL and its staging. NHL is divided into aggressive and indolent N...
Autores principales: | Amhaz, Ghid, Bazarbachi, Ali, El-Cheikh, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160834/ https://www.ncbi.nlm.nih.gov/pubmed/35663281 http://dx.doi.org/10.1016/j.lrr.2022.100325 |
Ejemplares similares
-
The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009) -
Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021) -
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021) -
Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021) -
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)